CNTA - Centessa Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

173.8M

Cash

346.2M

Avg Qtr Burn

-49.59M

Short % of Float

0.00%

Insider Ownership

1.86%

Institutional Own.

77.05%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SerpinPC Details Hemophilia	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB101 Details Cancer, Solid tumor/s	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imgatuzumab Details Solid tumor/s, Cancer, Cutaneous squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lixivaptan Details Kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.